VSEE HEALTH, INC. (VSEE): Entry into a Material Definitive Agreement
VSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 vseeex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 30, 2026, by and between VSee Health, Inc. , a Delaware corporation, with headquarters located at 980 N Federal Hwy, #304, Boca
How this was made
The 30-second read
Why it matters
This is a new capital raise via convertible debt. It may affect valuation through expected future dilution and can also influence liquidity expectations depending on the note’s cash cost and conversion schedule.
Market read
Convertible note financings often drive short-term volatility due to dilution overhang, making the specific conversion terms the key follow-up for traders.
What to watch
Traders should focus on the missing Note terms: conversion mechanics, any beneficial ownership caps, interest rate, maturity, and whether there are default or redemption provisions that could accelerate dilution or cash burn.
Background
The 8-K reports VSEE’s entry into a material definitive agreement, including a securities purchase agreement for a convertible promissory note sold in a private placement.
Ticker impact
VSEE entered a securities purchase agreement issuing a $300,000 purchase-price convertible promissory note with $336,000 aggregate principal.
Near-term trading may skew toward dilution/financing risk, with volatility around conversion terms and any subsequent equity issuance.
The 8-K is a primary disclosure of a convertible note transaction, but the excerpt does not provide conversion price, maturity, or discount details that would sharpen dilution and valuation impact.
Market effects
Convertible note financings can be a read-through for small-cap healthcare IT funding conditions, but this is company-specific and small in size.
No clear regional spillover indicated.
Limited global relevance; transaction is US private placement under Rule 506(b).
Counterpoint
If the note terms are favorable (e.g., limited dilution, longer maturity, or conversion at a premium), the market may over-discount the dilution risk.
Key entities
- issuerVSee Health, Inc.
Company filing the 8-K and issuing the convertible promissory note to the buyer.
- buyerLABRYS FUND II, L.P.
Accredited investor purchasing the note under Rule 506(b).
- counterpartyLabrys II Management, LLC
Receives $4,000 from the purchase price for due diligence costs per the agreement excerpt.
